The First Non-Invasive Treatment for Batten Disease is on its Way.

Polaryx Therapeutics, Inc. is dedicated to developing drug candidates for late infantile neuronal ceroid lipofuscinosis (LINCL) and other forms of NCL. Our strategy is to repurpose existing safe oral medications into effective easy to use dosing regimens for chronic treatment.

Contact Now

Why Polaryx?®

There’s an urgent need for novel, therapeutic interventions for Batten disease. That’s where Polaryx® comes in.

Learn More

The Technology

Discover our unique investigational methodology that polaryx is pursuing to treat Batten disease - non-invasively.

Learn More

The Strengths

Discover what’s holding back current treatments, and where Polaryx® excels.

Learn More

The Pipeline

Learn about the mechanism of action and drug repurposing strategy behind Polaryx®, and more.

Learn More

Meet the team

With over 100 years of combined experience, we're ready to take the fight to Batten disease.

Learn More

The Science

Learn more about Neuronal Ceroid Lipofuscinsosis (NCL), also known as Batten disease.

Learn More

Polaryx® Highlights

Repurposing of a safe and
previously approved compound
for a new condition

Pursuing pediatric
dosing options

Backed by an
experienced team

Potential to expand to
other subtypes of NCL, such
as JNCL and INCL

Completely
non-invasive
(taken orally)

Cost-effective drug
repurposing strategy

Latest News

Polaryx Therapeutics Received Orphan Drug Designation From the European Medicines Agency (EMA) for the Treatment of Neuronal Ceroid Lipofuscinosis With PLX-200
Polaryx® Featured in June 2017 Issue of Biopharma Dealmakers

Polaryx® Featured in June 2017 Issue of Biopharma Dealmakers

Renowned pharmaceutical industry publication, Biopharma Dealmakers, has featured Polaryx® Therapeturics in their June 2017 edition. Click "read more" now to view the publication.

Polaryx® interviewed by and featured in GHP magazine

Polaryx® interviewed by and featured in GHP magazine

To introduce Polaryx® and its technology, GHP magazine has interviewed the Polaryx® team. Click now to see the June 2017 GHP magazine edition. Polaryx® is featured on pages 26-27.

Polaryx Therapeutics Receives Orphan Drug Designation From the U.S. FDA for PLX-200 for Rare Pediatric Disease

Polaryx Therapeutics Receives Orphan Drug Designation From the U.S. FDA for PLX-200 for Rare Pediatric Disease

This new drug candidate will be used for the treatment of patients with Late Infantile Neuronal Ceroid Lipofuscinosis.

Polaryx Therapeutics Received Orphan Drug Designation From the European Medicines Agency (EMA) for the Treatment of Neuronal Ceroid Lipofuscinosis With PLX-200

Polaryx Therapeutics Receives Orphan Drug Designation From the US FDA for the Treatment of Neuronal Ceroid Lipofuscinoses With PLX-100

Polaryx Therapeutics, Inc. is a biotech company developing patient-friendly oral small molecule therapeutics for Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) and other forms of NCL, commonly known as Batten disease. Neuronal Ceroid Lipofuscinoses qualify as rare pediatric diseases under Section 529 of the Food, Drug, and Cosmetic Act.

We are seeking partners to help bring Polaryx's®
medications to children in need. Interested?

Click here to reach out.

Contact Now